<DOC>
	<DOCNO>NCT00626028</DOCNO>
	<brief_summary>A minimum 100 patient enrol study demonstrate diagnostic treatment ( oxygen nitric oxide ) capable identify patient reactive pulmonary vascular bed . Each patient give three treatment regimen , nitric oxide , oxygen , comparison treatment ( nitric oxide plus oxygen ) , wash period 10 minute dose . Patients randomized time enrollment determine comparison treatment receive .</brief_summary>
	<brief_title>Comparison Inhaled Nitric Oxide Oxygen Patient Reactivity During Acute Pulmonary Vasodilator Testing</brief_title>
	<detailed_description>This open , randomize , prospective , multi-center study design demonstrate diagnostic treatment capable identifying patient reactive pulmonary vascular bed . A minimum 100 patient enrol study compare number patient reversible pulmonary hypertension ( vasoreactivity ) due nitric oxide inhalation oxygen compare 100 % oxygen . This primary objective obtain measure decrease mean pulmonary arterial pressure ( PAPm ) ≥ 20 % decrease cardiac index ( within 5 % ) patient Idiopathic Pulmonary Arterial Hypertension ( IPAH ) Congenital Heart Disease ( CHD ) unrestricted shunt level ventricle ductus arteriosis , measure decrease PAPm ≥ 20 % decrease cardiac index ( within 5 % ) decrease pulmonary vascular resistance index ( PVRI ) ≥ 25 % decrease cardiac index ( within 5 % ) patient cardiomyopathy CHD unrestricted shunt level ventricle ductus arteriosis . Additionally , comparison incidence type drug relate serious adverse event well number patient reversible pulmonary hypertension due nitric oxide inhalation alone compare 100 % oxygen oxygen nitric oxide inhalation also assess .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<mesh_term>Vasodilator Agents</mesh_term>
	<criteria>1. must one three disease category : Idiopathic Pulmonary Arterial Hypertension PAPm &gt; 25mmHg rest , pulmonary capillary wedge pressure ( PCWP ) ≤ 15mmHg , PVRI &gt; 3 u•m^2 diagnose clinically previous catheterization CHD pulmonary hypertension repair unrepaired PAPm &gt; 25mmHg rest PVRI &gt; 3 u•m^2 diagnose clinically previous catheterization Cardiomyopathy PAPm &gt; 25mmHg rest PVRI &gt; 3 u•m^2 diagnose clinically previous catheterization 2 . Scheduled undergo right heart catheterization ass pulmonary vasoreactivity acute pulmonary vasodilation test . 3 . Male female , age 4 week 18 year , inclusive 4 . Signed informed consent/assent 1 . Focal pulmonary infiltrates chest radiograph . 2 . Diagnosed severe obstructive restrictive pulmonary disease significantly contribute patient 's pulmonary hypertension . 3 . Received treatment nitric oxide inhalation within 30 dyas prior study initiation , investigational medication , nitroglycerin , sodium nitroprusside , sildenafil , PDE5 inhibitor , prostacyclin 4 . Pregnant ( urine human chorionic gonadotropin ( HCG + ) positive ) 5 . Baseline PCWP &gt; 20 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pulmonary Vasculature</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>INOmax®</keyword>
	<keyword>Acute Lung Injury</keyword>
	<keyword>Pulmonary Vasodilator Testing</keyword>
	<keyword>Idiopathic Pulmonary Arterial Hypertension</keyword>
	<keyword>Congenital Heart Disease</keyword>
	<keyword>reversible pulmonary hypertension</keyword>
	<keyword>vasoreactivity</keyword>
</DOC>